Citadel Advisors
DICE

Citadel Advisors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Citadel Advisors’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-53,900
Closed -$2.5M – 15547
2023
Q2 		$2.5M Buy
53,900
+46,100
+591% +$1.59M ﹤0.01% 4763
2023
Q1 		$223K Sell
7,800
-500
-6% -$14.8K ﹤0.01% 9982
2022
Q4 		$259K Sell
8,300
-230,400
-97% -$7.51M ﹤0.01% 9625
2022
Q3 		$4.84M Buy
+238,700
New +$4.35M ﹤0.01% 3927

Citadel Advisors's DICE Position: Q3 2023 in Review

Citadel Advisors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 869 shares — an estimated $40.4K sold.

Citadel Advisors first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $14.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Citadel Advisors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 869 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $40.4K.
  • Citadel Advisors first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Citadel Advisors's DICE Therapeutics, Inc. Common Stock position peaked at $14.3M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.